Last reviewed · How we verify
ACC017 tablets
At a glance
| Generic name | ACC017 tablets |
|---|---|
| Also known as | ACC017/Placebo |
| Sponsor | Jiangsu Aidea Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase Ib/IIa Clinical Study of ACC017 Tablets (PHASE1, PHASE2)
- Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACC017 tablets CI brief — competitive landscape report
- ACC017 tablets updates RSS · CI watch RSS
- Jiangsu Aidea Pharmaceutical Group Co., Ltd. portfolio CI